We are live on ! Find out more

Humacyte

HUMA

Market cap $131M

0.4698 USD

-0.0003

0.06%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

0.4643

-0.0055

1.17%

1 day

-0.06%

5 days

11.86%

1 month

-11.81%

3 months

-24.78%

6 months

-42.71%

Year to date

-51.82%

1 year

-72.2%

5 years

-94.84%

10 years

-95.14%

About: Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Employees: 184

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.4%

Neutral 73.1%

Negative 11.5%

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.”

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

Zacks Investment Research

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Zacks Investment Research

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

See News Rankings

Price charts implemented using Lightweight Charts™